Nucleus RadioPharma, a Rochester, Minn.-based developer of technologies for radiopharmaceutical development, supply chain, and manufacturing, raised $6M in Seed funding.
Eclipse, a venture capital firm investing in the digital transformation of the world’s physical industries, and Mayo Clinic, a nonprofit health organization, created the company and provided the funding.
The company intends to use the funds to expand its development efforts.
Led by Charles S. Conroy, CEO, Nucleus RadioPharma is a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals by developing technologies to modernize the clinical development, manufacturing, and supply chain of these promising new therapies.
The founding Board of Directors is comprised of Manu Nair, Chair of Corporate Development at Mayo Clinic; Justin Butler, Partner at Eclipse; Mary Kate Wold, Chief Executive Officer and President of the Church Pension Group and a former senior executive at Wyeth; Ned Sharpless, M.D., former Director of the National Cancer Institute and former Acting Commissioner of the FDA; and Mike Rossi, former head of radioligand therapy and imaging at Novartis.
FinSMEs
18/10/2022